Organic Active Ingredients TRIZ Cases

A BTK-targeting degrader improves membrane permeability and degrades wild-type and BTK-C481S proteins to address ibrutinib-resistant tumors.

Oral pyrido[1,2-a]pyrimidinone analogs selectively inhibit PI3Kα in PIK3CA-mutated cancers to improve antitumor activity with fewer side effects.

Modulating Sphk2 and Pdk3 in HSPCs expands stem cell numbers, speeds hematopoietic recovery, and rejuvenates aged cells.

A closed TIL expansion process boosts cell yield in 10-22 days while lowering contamination risk, cost, and manufacturing complexity.

A biodegradable intravitreal implant uses a polymer matrix to sustain Edonentan release, improving ocular treatment efficacy with fewer side effects.

A membrane-isolated CO patch generates gas on demand at the skin while blocking toxic compounds and limiting systemic exposure.

Modified oligonucleotides reduce PLN RNA to improve cardiac calcium handling and contractility in heart failure and arrhythmia.

A PEgRNA directs Cas9 nickase and reverse transcriptase to install precise base changes and small indels without HDR or double-strand breaks.

By blocking SARM1-driven NAD+ loss, these compounds preserve axonal integrity and support treatment of neurodegenerative disorders.

A modular AMPK activator scaffold balances strong activation with easier synthesis and better stability for cancer and metabolic disease treatment.

Engineered EV binding agents target brain endothelial proteins to improve blood-brain barrier transport while avoiding known receptor safety risks.

Wet-granulated excipient ratios improve moisture and heat stability while keeping anti-arrhythmic tablets above 80% dissolution in 30 minutes.

Composite pullulan oral films balance fast dissolution with flexibility, high drug loading, and low moisture to avoid tackiness and microbial growth.

A biocompatible polymer composition helps repair and restore the blood-brain barrier by strengthening tight junctions and reducing permeability.

A small-molecule inhibitor targets LOXL2 over LOX to treat primary myelofibrosis while reducing off-target enzyme inhibition.

A green tea extract, ethanol, and succinic acid composition improves EGCG solubility, stable dispersion, and mold-free coffee capsule enrichment.

A mucoadhesive polymer gel reinforces cervical mucus by cross-linking without aggregation, blocking sperm and pathogens without hormonal side effects.

Dual MDM2 and FLT3 inhibition addresses resistance in FLT3-mutant AML while improving anti-cancer efficacy at lower dosing.

Pyrophosphato-platinum compounds accumulate in bone tissue to treat blood and bone cancers while improving efficacy and limiting toxicity.

Controlled crystallization turns an amorphous MAGL inhibitor into a stable solid form with better flow and capsule filling for pharmaceutical development.

A hydroxyl-group adhesive matrix with levulinic acid and methyl laurate boosts early ketamine flux while maintaining stability and skin tolerance.

A POH-rolipram carbamate targets temozolomide-resistant glioma cells and can sensitize tumors to radiation or chemotherapy.

Tri- and tetra-nucleotide mRNA cap analogues improve capping efficiency, simplify capped RNA purification, and boost protein expression in eukaryotic cells.

A cocoa fibre matrix controls limonene release to reach the colon, enable systemic absorption, and reduce mucosal irritation in obesity treatment.

Addresses the lack of effective FIP antivirals by combining niclosamide and spironolactone for practical multi-route treatment of FCoV infection.

A water-in-oil embolizing emulsion enables visible, temporary vessel occlusion to treat inflammatory hypervascularization in musculoskeletal disorders.

An osmotic multilayer methylphenidate composition creates a precise food- and pH-independent lag time, then releases in the lower GI tract.

A dual-surfactant magnetic microbubble composition raises cavitation threshold and stability for cyclic targeted delivery in high-flow vessels.

Novel glycolipid inhibitors block eIF4A-dependent or independent translation to address chemoresistance and broaden anticancer and antiviral use.

3D-printed intravaginal ring architectures use tunable unit-cell porosity to preserve drug stability and control long-acting release.

Novel acetamide derivatives selectively inhibit TGFβRI/ALK5 to curb fibrosis and inflammation while improving drug targeting in respiratory and ocular disease.

Novel Nox1-targeting compounds inhibit NADPH oxidase upstream to curb ROS production and avoid the limits of conventional antioxidants.

L-carnitine tartrate lowers ACE-2, Furin, and TMPRSS2 to limit coronavirus entry and help reduce cytokine storm risk.

Adding a physiologically acceptable salt to an oral dissolve ALA tablet reduces burning in the mouth while enabling rapid absorption of higher doses.

Bisquaternary ammonium compounds deliver 2-10 minutes of non-depolarizing muscle relaxation without reversal agents, using metabolic clearance alone.

A single nasal spray combines particulate mometasone and dissolved olopatadine to improve allergic rhinitis relief without added treatment complexity.

Microneedle delivery of plasma kallikrein inhibitors to the suprachoroidal space sustains posterior eye drug levels and reduces repeat injections.

Highly reactive 18F-labeled tetrazines use Cu-mediated fluorination to improve click kinetics, CNS access, and imaging contrast.

Blocking activin-A alongside chemotherapy helps curb tumor neovascularization and induce apoptosis in biomarker-selected ovarian cancer.

A segmented oral testosterone undecanoate formulation lowers peak plasma levels and reduces fluctuation through delayed release.

A nonabsorbable proton-binding polymer lowers acid load in CKD patients with eubicarbonatemic metabolic acidosis and helps raise serum bicarbonate.

A biphasic drotaverine formulation uses polymers and acidifying agents to limit degradation and maintain steadier plasma levels with once- or twice-daily dosing.

A defined monohydrate crystal form improves PDE9 inhibitor solubility, stability, and oral bioavailability for drug formulation.

Type II-C anti-CRISPR inhibitors bind Cas9 to control gene editing in space and time, reducing off-target cleavage and safety risks.

Modified oligonucleotides bind ATXN3 RNA to lower Ataxin-3 protein and aggregates, addressing disease progression in SCA3.

A triheterocyclic ATR inhibitor blocks tumor DNA repair, driving apoptosis in cancer cells while limiting harm to normal cells.

Segmented tafenoquine dosing keeps protective serum levels during and after exposure while improving tolerability for malaria-naïve subjects.

Covalent and cleavable linkers join oligonucleotide subunits to extend serum half-life while improving cellular delivery and internalization.

Targeting FUBP1 mRNA with enhanced antisense oligonucleotides helps destabilize HBV cccDNA and address chronic infection persistence.

Encapsulating high-GI carbohydrates in a gastric-resistant, ileal-sensitive carrier sustains energy release while limiting blood sugar spikes.

A TLR7 agonist paired with an HIV vaccine activates latent reservoirs and strengthens HIV-specific immunity to help delay viral rebound.

Shortened TIL expansion with IL-2, OKT-3, and reduced feeder-cell burden cuts manufacturing time, cost, and sterility risk for refractory NSCLC.

Sequential or concurrent tamoxifen, gefitinib, and vinorelbine target resistant cancers with broad activity and metronomic dosing.

Covalent nitrile compounds target the E1 catalytic cysteine to block SUMO modification and reduce cancer cell proliferation.

A degradable polymer film releases chemotherapy directly at pancreatic tumors to bypass poor vasculature and limit systemic toxicity.

A modified-release oral minoxidil formulation sustains serum levels for hair loss treatment while reducing peak-related adverse effects.

Blocking bradykinin receptors with antagonist compositions helps relieve bladder pain, burning, urgency, and lower urinary tract discomfort.

PTPN2-targeting heterocyclic compounds boost lymphoid cell activity to improve antitumor response while helping limit CAR-T toxicity.

An oxazole PDE4 inhibitor uses targeted substituent changes to strengthen inhibition while limiting nausea, vomiting, and systemic exposure.

A nasal spray combining glutamate antibodies, neurosteroids, and insulin helps acutely reduce concussion effects and stabilize excitatory neurotransmitters.

Novel compounds target SARS-CoV-2 Mpro to block viral replication and improve antiviral effect beyond modest existing COVID-19 treatments.

Sav1-targeting shRNA delivered to cardiomyocytes promotes heart muscle renewal in DMD, improving cardiac function and reducing fibrosis.

A cyclobenzaprine-mannitol eutectic with a basifying agent improves transmucosal delivery to reduce fibromyalgia pain, sleep disturbance, and fatigue.

Mesenchymal stem cells form gap junctions to transfer inhibitory oligonucleotides into target cells, improving cancer-directed delivery.

An alpha-lactalbumin lipid complex enables systemic treatment of distant and metastatic cancers while altering the tumor environment.

Separate pH-buffered semaglutide and cagrilintide chambers prevent injection-time particle formation while enabling one stable dose.

PEG-based self-emulsifying cannabinoid tablets resist stomach pH, improve GI uptake, and avoid poor mouthfeel at high loads.

Dual-binding compounds target androgen receptor and BRD4 to kill cancer cells, addressing resistance and side effects of current therapies.

An oil-in-water nanoemulsion keeps tacrolimus fully dissolved for long-term stability while improving particle uniformity and skin penetration.

Formula I GSPT1 degraders use structural changes such as deuteration to lower protein levels while addressing dose-limiting toxicity.

Compounds built to work with bound MTA keep PRMT5 inhibition effective in MTAP-deficient cells, supporting selective cancer treatment.

Controlled oral minoxidil release sustains serum levels for hair regrowth while limiting peak-related adverse effects.

Safer solvents, filtration, and crystallization replace toxic DMF and silica gel chromatography to enable GMP-scale alogabat production.

A phytic acid-metal-protein nanomaterial uses cation bridging to improve biocompatibility and persist at tumor sites for imaging and therapy.

C-20 amino-modified macrolides expand activity against resistant animal pathogens and mycoplasma while preserving strong antibacterial efficacy.

A saliva-activated rosuvastatin tablet uses disintegrants, mannitol, and sucralose to improve dissolution, taste masking, and swallowing.

A bicyclic small molecule is tuned for selective PARP-1 inhibition to block DNA repair while reducing intestinal and haematological toxicity.

Tocopherol-anchored DNA or RNA creates dense, stable sub-50 nm liposomal particles that resist fusion and enter cells without cationic agents.

Structural changes in α-ketoamide and oxamide ester compounds improve tyrosinase binding, solubility, and skin-whitening safety.

Combining an AKT inhibitor with fulvestrant suppresses breast tumor growth and clone formation while improving efficacy with lower toxicity.

A Serpinc1-targeting RNAi agent improves hemophilia bleeding control while enabling lower doses of replacement factors or bypassing agents.

Healthy donor γδ-T cells are expanded ex vivo and infused after lymphodepletion to improve antitumor response with low graft-versus-host risk.

Targets FLT3 resistance mutations such as F691L with a tailored inhibitor composition to sustain leukemia response and reduce recurrence.

Atomized droplet drying forms bioactive particles while avoiding heat, shaking, and stirring that can reduce biological activity.

Polymer-linked N-1 branched imidazoquinolines raise cytokine biosynthesis activity while preserving immune response modulation for viral and tumor therapy.

Electrically opened microchip reservoirs pair bolus dosing with membrane diffusion to reach therapeutic levels quickly and maintain them longer.

Direct perivascular delivery of cyclic everolimus esters slows washout, improves vessel retention, and helps prevent restenosis after vascular surgery.

Defined Forms I-III improve stability, solubility, and selectivity of a cardiac myosin modulator while reducing adverse effects.

Combining pyruvate and citrate boosts neuronal energy metabolism to limit seizure-related damage and epileptiform circuit formation.

Structurally diverse Formula I compounds inhibit DPAGT1 to treat infections and cancer while reducing cytotoxicity and improving selectivity.

Quaternary amine linkers with cleavable peptide segments improve ADC stability in circulation and release toxins inside tumor cells.

A succinimide-based cyclic connect unit improves HDAC inhibition and in vitro anti-tumor activity where conventional HDAC inhibitors underperform in solid tumors.

Mild acidic deprotection and controlled crystallization suppress polymerization and decomposition, improving purity and yield for scale-up.

Distinct steroid polymorphs use controlled crystallization and X-ray fingerprints to improve stability and pharmaceutical suitability for GABAA drugs.

A galactomannan-based ophthalmic emulsion extends ocular hydration, reduces blurring from oil globules, and lowers reapplication frequency.

FeCl3·6H2O in dichloromethane enables CBD synthesis from olivetol and terpene with high yield and minimal abn-CBD and bis-CBD by-products.

DHMBA suppresses preadipocyte growth and adipogenesis by modulating insulin signaling pathways, reducing lipid accumulation linked to obesity.

A cyclosporine solution in 1-perfluorobutyl-pentane enables twice-daily dry eye treatment with faster relief and fewer adverse effects.

Targeted R1 and R2 scaffold changes help FGFR inhibitors retain activity against wild-type and gatekeeper-mutant receptors.

Stable crystal forms replace degradable amorphous N-(benzoyl)-phenylalanine compounds, improving purity, solubility, and manufacturability.

By blocking renal glucose reuptake, this SGLT2 inhibitor composition lowers blood glucose while preserving beta-cell function and reducing cardiovascular risk.

A medicament depot patch delivers local anesthetic across closed wounds while adding support and barriers to reduce infection, dehiscence, and opioid use.

Floating gastro-retentive DAPTZ formulations release in the stomach to improve absorption and avoid distal gut side effects.

Modular HHC, H4CBD, and H4CBDV derivatives expand anti-cancer activity across cell lines and support combination use with chemotherapeutics.

Chiral organocatalysts enable gamma-carboline synthesis with high enantiomeric purity while avoiding transition metal impurities in CNS drug intermediates.

Targeted 2-heteroaryl pyridazine-4-carboxamides improve AHR inhibition to suppress tumour survival and treat cancer-related immune dysregulation.

Targeting GRP94 with a site-specific antibody-drug conjugate suppresses cetuximab-resistant CRC cells while reducing systemic toxicity.

Combining a quinoline TKI with anti-PD-1 or anti-PD-L1 antibodies helps break tumor immune tolerance and strengthen anti-tumor immunity.

Machine-learned senolytic compounds target Bcl-2 to clear senescent cells while improving safety and bioavailability over existing drugs.

New pyrimidine-based GABAA modulators treat CNS disorders by controlling brain excitability while addressing limits and side effects of older therapies.

By restoring endothelium-mediated vascular function, aurantiamide acetate lowers blood pressure with fewer side effects and better blood fluidity.

Non-viral BEST1 DNA vectors pair shRNA co-expression with electrotransfer to improve retinal delivery safety and durable BEST1 expression.

Novel aminosterol compositions use targeted sterol substitutions to inhibit PTP1B and address alpha-synuclein and dopaminergic disorders.

Atovaquone inhibits mast cell degranulation to treat inflammatory disease while avoiding the side effects and dependence linked to corticosteroids.

Liquid-filled soft gelatin capsules improve low-dose talazoparib uniformity and stability while supporting flexible batch sizes.

Targets the AR N-terminal domain to inhibit and degrade full-length and splice-variant receptors that evade LBD-directed therapy.

Using the 2S,4R ketoconazole enantiomer reduces androgen excess and aldosterone while avoiding 11-DOC burden and hepatotoxicity.

Cyclic substitution at steroid position 10 improves GABA receptor modulation to treat CNS disorders by altering brain excitability and chloride conductance.

Photo-crosslinked dendrimer-bioadhesive hydrogel seals corneal wounds with strong biocompatibility and sustained ocular drug release.

An amorphous uridine triacetate dispersion with HPMCAS-MG improves oral bioavailability while preventing crystal formation during storage.

Radiolabeled DREADD agonists improve hM3Dq and hM4Di affinity, brain penetrance, and non-invasive receptor imaging without fluorescent reporters.

A mixed suspension-solution keeps palonosetron dissolved and netupitant suspended to maintain homogeneity and oral dosing stability.

An imidazole-linked DNP prodrug enables gradual mitochondrial uncoupling to raise energy expenditure while lowering toxicity risk.

Sequence-specific dsRNA degrades apo(a) mRNA to lower Lipoprotein(a) when direct Lp(a) targeting lacks selective therapeutic options.

Topical or oral aminopyridine compounds trap toxic aldehydes in vivo, reducing ocular inflammation and tear film damage in xerophthalmia.

A receptor antagonist composition case showing how structural variation improves solubility, stability, bioavailability, and safety in P2X3-targeted therapy.

Lipid-linked JAK inhibitors target lymphatic tissues to bypass first-pass metabolism, improve bioavailability, and reduce systemic toxicity.

Heterocyclic GLP-1 agonists improve insulin secretion and glucagon suppression to lower fasting glucose, HbA1c, and BMI in T2DM.

Selective PRMT5 inhibitors curb gene silencing, raise p53 and γ-gene expression, and support treatment of cancer and hemoglobin disorders.

Specific inositol phosphate dosing inhibits hydroxyapatite formation in calciphylaxis, reducing pain, lesion severity, and healing time.

An LLP2A-bisphosphonate conjugate guides mesenchymal stem cells to inflamed joints, improving immunoregulation and limiting bone loss.

Human SNHG14-targeting oligonucleotides induce paternal UBE3A in neurons while avoiding effects on SNORD115 and SNRPN transcripts.

Benzo nitrogen-containing heteroaromatic compounds inhibit complement factor B while balancing bioavailability and safety for C3a-linked disease treatment.

A CAI-PLGA nanoemulsion enables local ocular delivery to overcome poor solubility and systemic side effects while maintaining therapeutic efficacy.

Amidine compounds boost antibiotic activity against resistant bacteria, improving treatment options while avoiding the toxicity of higher doses.

Direct sGC activators based on pyrazolo piperidine carboxylic acids improve pharmacokinetics while avoiding NO-dependent tolerance.

Targeting the ERK1/2 substrate docking site curbs AP-1-driven airway remodeling while reducing resistance and toxicity seen with ATP-site inhibitors.

A two-part omeprazole kit uses a buffered surfactant diluent to keep suspensions homogeneous and resist gel formation after freeze-thaw cycles.

A combined antioxidant composition improves resistance to DNA damage, oxidative stress, and mitochondrial dysfunction while supporting DNA repair.

A single-phase hydroalcoholic diclofenac gel removes oily residue, stays transparent, and keeps skin permeation within emulgel-like limits.

Selective cJAK-1 inhibitors extend dosing to once daily while maintaining anti-inflammatory efficacy and improving tolerability in canine atopic dermatitis.

A nonionic surfactant and controlled particle size keep this dry eye ophthalmic suspension uniformly redispersible for more consistent dosing.

Selective lfTSLP-targeting oligonucleotides reduce airway inflammation and mucus while preserving short-form TSLP antimicrobial protection.

Small molecules combine sEH and QC inhibition to reduce neuroinflammation and amyloid pathology while retaining BBB permeability.

ALT-803 pairs an IL-15 superagonist with IL-15Rα/Fc to boost memory T cells and long-lasting anti-myeloma immune response.

Low-oxygen, pH-controlled dopamine injection stays stable for 7 days at 37°C, enabling continuous anaerobic pump delivery with less oxidation.

A maralixibat solid dosage composition uses excipients and particle control to balance rapid acidic dissolution with storage stability.

A dissolved fluticasone HFA formulation with coated canister, metering valve, and dose counter reduces ripening, deposition, and dose variability.

Targeting elevated mitochondrial Complex II with Coenzyme Q10 induces apoptosis in TMZ-resistant glioma while limiting toxicity.

Chemically linked liver-targeting siRNA suppresses FXI expression with high specificity and stability to help prevent thrombosis and ischemic stroke.